Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.

Li X, Semenova S, D'Souza MS, Stoker AK, Markou A.

Neuropharmacology. 2014 Jan;76 Pt B:554-65. doi: 10.1016/j.neuropharm.2013.05.042. Epub 2013 Jun 7. Review.

2.

The "stop" and "go" of nicotine dependence: role of GABA and glutamate.

D'Souza MS, Markou A.

Cold Spring Harb Perspect Med. 2013 Jun 1;3(6). pii: a012146. doi: 10.1101/cshperspect.a012146. Review.

4.
5.

Neuroscience of nicotine for addiction medicine: novel targets for smoking cessation medications.

D'Souza MS.

Prog Brain Res. 2016;223:191-214. doi: 10.1016/bs.pbr.2015.07.008. Epub 2015 Nov 23. Review.

PMID:
26806777
6.

Metabotropic glutamate receptor 5 as a potential target for smoking cessation.

Chiamulera C, Marzo CM, Balfour DJK.

Psychopharmacology (Berl). 2017 May;234(9-10):1357-1370. doi: 10.1007/s00213-016-4487-3. Epub 2016 Nov 16. Review.

PMID:
27847973
7.

Review. Neurobiology of nicotine dependence.

Markou A.

Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3159-68. doi: 10.1098/rstb.2008.0095. Review.

8.

Endogenous opioid system: a promising target for future smoking cessation medications.

Norman H, D'Souza MS.

Psychopharmacology (Berl). 2017 May;234(9-10):1371-1394. doi: 10.1007/s00213-017-4582-0. Epub 2017 Mar 11. Review.

PMID:
28285326
9.

New mechanisms and perspectives in nicotine withdrawal.

Jackson KJ, Muldoon PP, De Biasi M, Damaj MI.

Neuropharmacology. 2015 Sep;96(Pt B):223-34. doi: 10.1016/j.neuropharm.2014.11.009. Epub 2014 Nov 26. Review.

10.

Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R.

Neurosci Biobehav Rev. 2010 Nov;35(2):220-31. doi: 10.1016/j.neubiorev.2010.02.006. Epub 2010 Feb 16. Review.

11.

Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Fowler CD, Kenny PJ.

Neuropharmacology. 2014 Jan;76 Pt B:533-44. doi: 10.1016/j.neuropharm.2013.09.008. Epub 2013 Sep 18. Review.

12.

Nicotinic receptor-based therapeutics and candidates for smoking cessation.

Dwoskin LP, Smith AM, Wooters TE, Zhang Z, Crooks PA, Bardo MT.

Biochem Pharmacol. 2009 Oct 1;78(7):732-43. doi: 10.1016/j.bcp.2009.06.002. Epub 2009 Jun 10. Review.

13.

Double target concept for smoking cessation.

Wu J.

Acta Pharmacol Sin. 2010 Sep;31(9):1015-8. doi: 10.1038/aps.2010.137. Epub 2010 Aug 16.

14.

Stimulation of lateral hypothalamic glutamate and acetylcholine efflux by nicotine: implications for mechanisms of nicotine-induced activation of orexin neurons.

Pasumarthi RK, Fadel J.

J Neurochem. 2010 May;113(4):1023-35. doi: 10.1111/j.1471-4159.2010.06666.x. Epub 2010 Mar 4.

15.

Targeting glutamate homeostasis for potential treatment of nicotine dependence.

Alasmari F, Al-Rejaie SS, AlSharari SD, Sari Y.

Brain Res Bull. 2016 Mar;121:1-8. doi: 10.1016/j.brainresbull.2015.11.010. Epub 2015 Nov 14. Review.

16.

Prefrontal gamma-aminobutyric acid type A receptor insertion controls cue-induced relapse to nicotine seeking.

Lubbers BR, van Mourik Y, Schetters D, Smit AB, De Vries TJ, Spijker S.

Biol Psychiatry. 2014 Nov 1;76(9):750-8. doi: 10.1016/j.biopsych.2014.02.001. Epub 2014 Feb 11.

PMID:
24631130
17.
18.

Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Buchhalter AR, Fant RV, Henningfield JE.

Drugs. 2008;68(8):1067-88. Review.

PMID:
18484799
19.

Mechanism-based medication development for the treatment of nicotine dependence.

Xi ZX, Spiller K, Gardner EL.

Acta Pharmacol Sin. 2009 Jun;30(6):723-39. doi: 10.1038/aps.2009.46. Epub 2009 May 11. Review.

20.

Emerging pharmacotherapies for smoking cessation.

Garwood CL, Potts LA.

Am J Health Syst Pharm. 2007 Aug 15;64(16):1693-8. Review. Erratum in: Am J Health Syst Pharm. 2007 Oct 1;64(19):1995.

PMID:
17687057

Supplemental Content

Support Center